MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Complement Inhibitors

Search medical newsFind research, conditions and clinical updates
  • Home
  • Complement Inhibitors
Comparative Effectiveness and Safety of Emerging Myasthenia Gravis Therapies: Insights From a Bayesian Network Meta-Analysis
Posted inNeurology news

Comparative Effectiveness and Safety of Emerging Myasthenia Gravis Therapies: Insights From a Bayesian Network Meta-Analysis

Posted by By MedXY 07/20/2026
A Bayesian network meta-analysis comparing FcRn inhibitors, C5 complement inhibitors, and CD19+ B-cell depletion therapies reveals comparable efficacy but varied safety profiles in generalized myasthenia gravis treatment, highlighting the need for prospective head-to-head trials.
Read More
Understanding Patient Acceptance of Complement Inhibitor Therapy in Geographic Atrophy
Posted inOphthalmology Pediatrics Specialties

Understanding Patient Acceptance of Complement Inhibitor Therapy in Geographic Atrophy

Posted by By MedXY 09/28/2025
A UK study reveals most patients with geographic atrophy are open to intravitreal complement inhibitor injections if these treatments offer vision improvement, highlighting the vital role of functional benefits in therapy acceptance.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Navigating Parental Refusal of Optimal Pediatric Cancer Treatments: Ethical Nuances of Trust and Nudging in Clinical Care
  • Ultrasound-Detected Presynovitis Predicts Rheumatoid Arthritis Onset in ACPA-Positive Individuals
  • Operationalizing Cardiac Xenotransplantation: A Comprehensive Administrative Playbook for Clinical Implementation
  • Brepocitinib Shows Promising Efficacy and Safety in Cutaneous Sarcoidosis: Results from a Phase 2 Randomized Clinical Trial
  • Evaluating the Impact of Timing on Cleft Palate Closure Outcomes: Insights from a Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top